Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Elevai Labs, Inc. Common Stock (ELAB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: ELAB (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
0 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
Analysis of Past Performance
Type Stock | Historic Profit 0% | Avg. Invested days 0 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 2.94M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta - | 52 Weeks Range 1.95 - 839.86 | Updated Date 06/29/2025 |
52 Weeks Range 1.95 - 839.86 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -9.44 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -36.92% | Return on Equity (TTM) -95.21% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -3351530 | Price to Sales(TTM) 2.34 |
Enterprise Value -3351530 | Price to Sales(TTM) 2.34 | ||
Enterprise Value to Revenue 2.59 | Enterprise Value to EBITDA - | Shares Outstanding 1375380 | Shares Floating 1259303 |
Shares Outstanding 1375380 | Shares Floating 1259303 | ||
Percent Insiders 0.49 | Percent Institutions 2.99 |
Upturn AI SWOT
Elevai Labs, Inc. Common Stock
Company Overview
History and Background
Elevai Labs, Inc. focuses on developing and marketing topical aesthetic skincare products. Founded relatively recently, the company aims to innovate in the medical aesthetics sector.
Core Business Areas
- Topical Skincare Products: Develops and commercializes topical aesthetic skincare products for skin rejuvenation and improvement.
- Professional Skincare Solutions: Provides solutions to medical aesthetic professionals, supporting their in-clinic offerings.
Leadership and Structure
Details about the executive team and organizational structure are needed. Public information on this is sparse.
Top Products and Market Share
Key Offerings
- Exosomes Skincare: Elevai offers topical cosmetic exosome products, believed to have skin-rejuvenating properties. Competitors include companies that sell growth factors and other regenerative skincare products.
- Elevai E-Series: A line of topical skincare products designed to support skin health and address specific concerns. Competitors include well-established skincare brands (e.g., SkinCeuticals, Obagi).
Market Dynamics
Industry Overview
The aesthetic skincare market is growing, driven by increasing consumer demand for anti-aging and skin-rejuvenating products and procedures.
Positioning
Elevai Labs aims to be a leader in the medical aesthetics market through innovative science-backed topical solutions.
Total Addressable Market (TAM)
The global skincare market is estimated to be worth billions of dollars annually, with the professional skincare segment accounting for a significant portion. Elevai is positioned to capture a share of this expanding market. The professional skincare market is projected to reach $168 billion in 2024. Market is expected to grow to $209.60 billion by 2029.
Upturn SWOT Analysis
Strengths
- Innovative products
- Focus on medical aesthetics
- Potential for rapid growth in a growing market
Weaknesses
- Limited operating history
- Small market share
- Dependence on key products
- Less Brand recognition and limited marketing budget relative to established brands
Opportunities
- Expanding product line
- Partnering with medical professionals
- Entering new geographic markets
- New delivery technologies and methods
Threats
- Competition from established brands
- Regulatory changes
- Economic downturns
- Changing consumer preferences
- Imitation and IP risk
Competitors and Market Share
Key Competitors
- ALGN
- LULU
- ESTE
Competitive Landscape
Elevai faces intense competition in the aesthetic skincare market, particularly from larger, more established players. The company's success depends on its ability to innovate and differentiate its products.
Growth Trajectory and Initiatives
Historical Growth: Growth requires access to historical financial performance data, currently unavailable.
Future Projections: Future projections are based on market trends and company strategy. Accurate projections need analyst reports and financial data that is not available here.
Recent Initiatives: Recent initiatives may include product launches, partnerships, and market expansion efforts. Specific details are unavailable without further data.
Summary
Elevai Labs is an emerging player in the aesthetic skincare market with innovative products and a focus on medical aesthetics. Its small market share and limited operating history present challenges. Its success will depend on expanding its product line, partnering with medical professionals, and entering new geographic markets, as well as navigating a landscape filled with well-established competitors and evolving regulatory requirements.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- Market Reports
- Third Party Financial Data Providers
Disclaimers:
The data and analysis provided are based on available information and should not be considered financial advice. Market conditions are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Elevai Labs, Inc. Common Stock
Exchange NASDAQ | Headquaters Newport Beach, CA, United States | ||
IPO Launch date 2023-11-21 | CEO, CFO, Secretary & Director Mr. Graydon Bensler C.F.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 2 | Website https://pmgcholdings.com |
Full time employees 2 | Website https://pmgcholdings.com | ||
PMGC Holdings Inc., a biopharmaceutical company, focuses on the development and acquisition of cutting-edge aesthetic medicines and therapeutic products. The company's lead product includes EL-22, a first-in-class engineered probiotic approach to address obesity's pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists. It is also involved in the medical scientific research and development activities, as well as operates investment firms. The company was formerly known as Elevai Labs, Inc. and changed its name to PMGC Holdings Inc. in December 2024. PMGC Holdings Inc. was incorporated in 2020 and is based in Newport Beach, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.